Endotoxin receptor CD14 gene variants and histological features in chronic HCV infection

Table 4 Histological features in chronic hepatitis C-infected patients with regard to CD14 rs2569190 genotype (UMG group) n (%)

Histological features	CD14 rs2569190 genotype				MAF	aP
	CC	CT	TT	aP
Hepatitis activity
Mild	19 (25.0)	40 (52.6)	17 (22.4)	0.172b	0.487	0.152
Moderate	10 (19.2)	24 (46.2)	18 (34.6)		0.574
Severe	1 (11.1)	6 (66.7)	2 (22.2)
Fibrosis
Absent	7 (38.9)	6 (33.3)	5 (27.8)	0.758b	0.517	0.727
Mild	14 (20.6)	35 (51.5)	19 (27.9)
Moderate	5 (19.2)	15 (57.7)	6 (23.1)
Marked	3 (21.4)	7 (50.0)	4 (28.6)		0.539
Cirrhosis	1 (9.1)	7 (63.6)	3 (27.3)
Steatosis
Absent	14 (23.3)	28 (46.7)	18 (30.0)	0.695b	0.528	0.887
Mild	10 (20.8)	26 (54.2)	12 (25.0)
Moderate	5 (26.3)	10 (52.6)	4 (21.1)		0.517
Marked	1 (10.0)	6 (60.0)	3 (30.0)
Portal lymphoid aggregates
Absent	22 (26.2)	46 (54.8)	16 (19.1)	0.008b	0.464	0.011
Present	8 (15.1)	24 (45.3)	21 (39.6)		0.623
Bile duct damage
Absent	21 (23.6)	46 (51.7)	22 (24.7)	0.411b	0.506	0.368
Present	9 (18.8)	24 (50.0)	15 (31.3)		0.563

^aχ² test was applied to compare mild vs moderate and severe hepatitis activity, absent, mild vs moderate and marked fibrosis and cirrhosis, and absent, mild vs moderate and marked steatosis;

^bC carriers vs TT.